Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

| More on:
Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have slipped 9.77% over the past month, leaving some investors questioning whether the global biotech heavyweight is facing new headwinds.

This comes as international stock markets roar to new heights following the outcome of the recent US election.

Despite this, CSL shares have been heavily sold. At the time of writing, they are trading near three-month lows at $272.30 apiece.

With the company reaffirming robust FY25 guidance, is now a golden buying opportunity or a warning sign for ASX investors? Let's see.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

What's behind the dip in CSL shares?

The slide in CSL shares coincides with a selloff in the broader healthcare sector, likely fuelled by geopolitical and regulatory concerns.

Today, healthcare stocks as a basket are down more than 1%, joined by the IT and financial sectors, which are also in the red.

Meanwhile, reports have surfaced surrounding US president-elect Donald Trump's choice to head the US Department of Health and Human Services: Robert F Kennedy Jr (or RFK as he is known).

Reporting from The Guardian says that global pharmaceuticals stocks sold off last week after the news was announced.

"The potential ramifications of RFK Jr running the department prompted panic among investors with shares [in pharmaceutical stocks]," it said.

Wait, what? Hold up a moment…

Let's take a step back here for a second and nut out how this relates to CSL shares.

A fundamental principle in statistics is that correlation does not (emphasis added) equal causation.

For instance, there could be an increasing trend for the number of sunny days in a year and the number of cats falling off rooftops.

Does that mean sunny days cause cats to fall off roofs? Or, that cats falling off rooftops causes the sun to shine? No.

The appointment of an elected official does not change a business's fundamental outlook, at least not overnight.

The same is true for CSL shares.

Brokers are bullish

That's why, while these factors may have spooked investors in the very short term, analysts remain bullish on the outlook for CSL shares.

At the company's annual general meeting in October, management reaffirmed FY25 guidance, projecting net profit between US$3.2 billion and US$3.3 billion.

This equates to growth of 10% to 13% — a sign that the biotech continues to deliver strong fundamentals despite market turbulence, supporting growth in CSL shares.

CSL's guidance has been met with widespread confidence from brokers.

Ord Minnett rates CSL shares as a buy, citing its margin recovery phase and consistent earnings growth. Analyst Tony Paterno noted that fluctuating exchange rates might shave off around US$50 million from FY25 figures, but this impact was expected to be minimal.

Bell Potter also sees potential upside, noting that CSL currently trades at a discount to its 10-year average forward price-to-earnings (P/E) ratio of 311 times.

Meanwhile, Citi has set a bullish price target of $345 for CSL shares, implying plenty of upside from current levels.

Finally, Morgans has also thrown its weight behind CSL shares, forecasting annual double-digit earnings growth over the mid-term.

Should you buy CSL shares now?

While the recent dip in CSL shares might unsettle some investors, the company's fundamentals remain strong.

On that point, it's essential to keep a long-term view in mind. Markets will overreact to the upside and downside, providing opportunities.

More important are the factors of business valuation, performance and the broader economy – not the headlines.

In the last 12 months, the stock is up 5.3%.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »